Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- (4Z)-4-(2-amino-1,5-dihydro-5-oxo-4H-imidazol-4-ylidene)-4,5,6,7-tetrahydro-pyrrolo[2,3-c]azepin-8(1H)-one
- Correlated keywords
- 96562-99-1 natural products inhibitors inhibits inhibitions kinases cells cycles DNA damages Chks Chk-1 Chk-2 Chk1 Chk2 1 2 one two checkpoint kinases marine sponge alkaloids blocks blockage blocking G2 arrest repairs regulation regulates regulated MAP kinases 1 MEK-1 MEK1 MEKs glycogen synthase kinase-3b GSK-3b kinase-3beta kinase-3.beta. kinase-3 ? K-3 ? K-3.beta. K-3beta K-3b GSKs cyclin-dependent cyclin dependent 5 five p25 CDKs Cdk5 Cdk-5 protein tyrosine 6 Brk SKF108753 SKF-108753 SKFs 108753 Z-debromohymenialdisine 96562-99-1 humans sensor signals checkpoints ataxia telangiectasia mutated ATM ATM-Tad2 Tad2 MAP
- Product Overview:
Damaged DNA in humans is detected by sensor proteins that transmit a signal through checkpoint kinases (Chks) Chk1 and Chk2.{24026} Debromohymenialdisine (DBH) is a marine sponge alkaloid that inhibits Chk1 and Chk2 (IC50 = 3 and 3.5 µM, respectively), blocking G2 arrest.{24024,24029} Because it does not significantly affect the activity of ataxia-telangiectasia mutated (ATM) or ATM-Tad2-related protein, DBH is a useful tool for studying the roles of Chk1 and Chk2 in DNA repair and cell cycle regulation.{24024} DBH also inhibits MAP kinase kinase 1 (IC50 = 881 nM), glycogen synthase kinase 3? (IC50 = 1.39 ?M), cyclin-dependent kinase 5/p25 (IC50 = 9.12 ?M), protein tyrosine kinase 6 (IC50 = 0.6 ?M), and other kinases largely unrelated to DNA damage/repair and cell cycling.{24027,24028,24025,24023}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.